Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dr Soliman Abdul Kader Fakeeh Hospital Co EV-to-EBITDA?
Dr Soliman Abdul Kader Fakeeh Hospital CoSAU:4017 +2.55%15 EV-to-EBITDA is 21.76 as of Sep. 14, 2026, which is 6% above its 10-year median of 20.53. GuruFocus rates SAU:4017 with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 518 Healthcare Providers & Services companies, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks worse than 78.19% on this metric.
SAU:4017's EV-to-EBITDA is ranked worse than 78.19% of 518
companies
in the Healthcare Providers & Services industry
Industry Median: 10.365
vs SAU:4017: 21.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dr Soliman Abdul Kader Fakeeh Hospital Co's PE Ratio (TTM) for today is calculated as:
Dr Soliman Abdul Kader Fakeeh Hospital Co's share price for today is ﷼39.44.
Dr Soliman Abdul Kader Fakeeh Hospital Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼1.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Soliman Abdul Kader Fakeeh Hospital Co EV-to-EBITDA Chart
Dr Soliman Abdul Kader Fakeeh Hospital Co Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-EBITDA
0.00
29.93
17.57
Dr Soliman Abdul Kader Fakeeh Hospital Co Quarterly Data
SAU:4017 vs HCA, THC, EHC: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Soliman Abdul Kader Fakeeh Hospital Co EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA falls into.
Dr Soliman Abdul Kader Fakeeh Hospital Co's current Enterprise Value is ﷼10,496 Mil.
Dr Soliman Abdul Kader Fakeeh Hospital Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼482 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017) has a EV-to-EBITDA of 21.76 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dr Soliman Abdul Kader Fakeeh Hospital Co. This is near median its historical median of 20.53. Over the past decade, Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA has ranged from 15.65 to 31.06. According to the industry distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #405 out of 518 companies in the Healthcare Providers & Services industry, placing it in the top 78.2%.
Is Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA too high?
Dr Soliman Abdul Kader Fakeeh Hospital Co's current EV-to-EBITDA of 21.76 is near median its 10-year median of 20.53. Over the past 10 years, this metric has ranged from a low of 15.65 to a high of 31.06. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.37. Dr Soliman Abdul Kader Fakeeh Hospital Co's value of 21.76 is 109.9% above this industry median. Based on the distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #405 out of 518 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dr Soliman Abdul Kader Fakeeh Hospital Co has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Dr Soliman Abdul Kader Fakeeh Hospital Co's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #405 out of 518 companies for EV-to-EBITDA. This places Dr Soliman Abdul Kader Fakeeh Hospital Co in the lower half of its industry. The industry median EV-to-EBITDA is 10.37. Dr Soliman Abdul Kader Fakeeh Hospital Co's value of 21.76 is 109.9% above this benchmark. Historically, Dr Soliman Abdul Kader Fakeeh Hospital Co's own EV-to-EBITDA has ranged from 15.65 to 31.06 over the past decade. While the company's 10-year median is 20.53 vs. the industry median of 10.37, Dr Soliman Abdul Kader Fakeeh Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.37, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Soliman Abdul Kader Fakeeh Hospital Co's current EV-to-EBITDA of 21.76 is 109.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dr Soliman Abdul Kader Fakeeh Hospital Co. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Soliman Abdul Kader Fakeeh Hospital Co's current EV-to-EBITDA is 21.76, which is near median its own 10-year median of 20.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Soliman Abdul Kader Fakeeh Hospital Co stock overvalued right now?
Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017) has a current EV-to-EBITDA of 21.76. The current EV-to-EBITDA is 21.76, which is near median its 10-year median of 20.53 and 109.9% above the Healthcare Providers & Services industry median of 10.37. Dr Soliman Abdul Kader Fakeeh Hospital Co's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017), the current EV-to-EBITDA is 21.76 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dr Soliman Abdul Kader Fakeeh Hospital Co is a company whose principal activities include managing, establishing, and operating hospitals, clinics, medical, educational, and training centers. In addition to the above, the company is also managing and operating medical services, analysis and radiology laboratory, and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment, and software-related services. The group has three reportable segments, including medical services, which generates maximum revenue, education, trading, retail, and others. Geographically, it principally operates in the Kingdom of Saudi Arabia.
15GF Score
Get the complete analysis for SAU:4017
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4017 has been successfully added to your 
